Florida / New York / No Carolina
Ph: 561.316.3330

MilliporeSigma Announces Completion of Schnelldorf Distribution Center Expansion

MilliporeSigma announced that its Life Science business opened a newly expanded distribution center in Schnelldorf, Germany

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • The Life Science business of Merck KGaA, Darmstadt, Germany is comprised of more than 50 production and testing sites and 64 distribution centers around the world and has more than 27,000 employees in 65 countries.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that its Life Science business has opened a newly expanded distribution center in Schnelldorf, Germany. The investment of € 180 million added 25,000 square meters to the site, almost doubling its size. It now includes a new manual down filling operation and additional space for the distribution of a wide range of products to laboratories and research facilities all around the world. The site employs 470 engineers, manufacturing, and distribution experts.

By combining manual downing filling capabilities with our distribution expertise, our customers will benefit from increased product availability and quicker delivery,” said Matthias Heinzel, Member of the Executive Board and CEO Life Science, Merck KGaA, Darmstadt, Germany. “This is critical to ensuring that medicines reach patients faster, safely, and more efficiently. This is how we do our part to impact life and health with science.”

“With this expansion, Schnelldorf is becoming one of our flagship sites, providing unique end-to-end capabilities for our Life Science customers,” said Ivan Donzelot, Head of Integrated Supply Chain Operations, Life Science business of Merck KGaA, Darmstadt, Germany. “With the full integration of manufacturing and distribution in one site, our customers can now receive even faster and better service whether they are in Europe or in other regions of the world.”

The expansion of the Schnelldorf facility is part of a multi-year investment program of the company’s Life Science business. It aims to increase the capacity and capabilities to support the growing global demand for critical drugs and to make significant contributions to public health. Since 2020, the Life Science business of Merck KGaA, Darmstadt, Germany has announced industrial capacity and capabilities expansion projects in Life Science throughout Europe, China, and the United States, of more than € 2 billion.

The Life Science business of Merck KGaA, Darmstadt, Germany is comprised of more than 50 production and testing sites and 64 distribution centers around the world and has more than 27,000 employees in 65 countries.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. "We are proud to contribute to the fight against AML through our SOPHiA DDM™ RAM Solution. In particular we feel that the capability to seamlessly track longitudinally the evolution of individual mutations over time through a dedicated add-on module of our SOPHiA DDM™ Platform has the potential to be a game-changer for clinical researchers."

Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001

Sterling Chung, Vice President of Regulatory Affairs and Quality at Aurion Biotech. “These designations underscore the importance of developing a potential solution for millions of patients around the world who suffer from corneal endothelial diseases. We look forward to working closely with the FDA to expedite the development of our cell therapy.”

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study.

By using this website you agree to accept Medical Device News Magazine Privacy Policy